Core Viewpoint - ClaimsFiler informs investors about the deadline to file lead plaintiff applications in securities class action lawsuits against Organon & Co. for the Class Period from October 31, 2024, to April 30, 2025 [1] Group 1: Lawsuit Details - Organon and certain executives are accused of failing to disclose material information during the Class Period, violating federal securities laws [3] - The first-filed case is Hauser v. Organon & Co., et al., and a subsequent case, Lerner v. Organon & Co., et al., expanded the class period [5] Group 2: Financial Impact - On March 10, 2025, Organon announced a significant reduction in its dividend payout from $0.28 to $0.02, which contradicted previous assurances to investors [4] - Following the dividend announcement, Organon's share price dropped over 27%, from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [4] Group 3: Investor Support - ClaimsFiler provides resources for investors to recover funds from securities class action settlements, including free registration for information access and case evaluations [6]

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Petco Health and Wellness Company, Inc. ("Petco" or the "Company") (NASDAQ: WOOF) investors of a class action representing investors that bought securities between January 14, 2021 and June 5, 2025, inclusive (the "Class Period"). Petco investors have until August 29, 2025 to file a lead plaintiff motion. Investors are encouraged to contact att ...

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation, alleging that the company misrepresented the effectiveness of its restructuring plan following a failed merger with Amazon, leading to significant investor losses [3][4]. Group 1: Lawsuit Details - The class action represents investors who purchased iRobot securities between January 29, 2024, and March 11, 2025, with a deadline of September 5, 2025, to file a lead plaintiff motion [1]. - The lawsuit claims that iRobot overstated the stability provided by its restructuring plan, raising doubts about its long-term viability as an independent company [3]. Group 2: Financial Performance - iRobot reported a loss of $2.06 per share for Q4 and the full year 2024, with revenue of $172 million, marking a 44% decline from the previous year [4]. - The company's statement indicated "substantial doubt" about its ability to continue as a going concern for at least the next 12 months, which led to a stock price drop of over 51% following the announcement [4].

Core Viewpoint - Hims & Hers Health, Inc. is facing two securities class action lawsuits due to allegations of deceptive marketing practices and failure to disclose critical information, particularly related to its collaboration with Novo Nordisk and the weight loss drug Wegovy® [1][4][5] Group 1: Lawsuits and Allegations - Two class action lawsuits were filed against Hims & Hers Health, Inc. and certain executives, representing investors who acquired securities between April 29, 2025, and June 23, 2025 [1] - The lawsuits allege that Hims & Hers made false and misleading statements and engaged in deceptive promotion of knockoff versions of Wegovy®, which jeopardized patient safety and led to the termination of its collaboration with Novo Nordisk [4][5] - The lawsuits were prompted by Novo Nordisk's announcement on June 23, 2025, that it terminated its collaboration due to concerns over Hims & Hers' illegal practices and deceptive marketing [2][5] Group 2: Investor Impact and Actions - Following the termination of the collaboration, Hims & Hers shares experienced a significant decline of 30% [2] - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to submit their losses [3][6] - The lead plaintiff deadline for the lawsuits is set for August 25, 2025 [3] Group 3: Whistleblower Information - Individuals with non-public information regarding Hims & Hers are encouraged to assist in the investigation or consider the SEC Whistleblower program, which offers rewards for original information leading to successful recoveries [7]

RT CoinDesk (@CoinDesk)NOW: 🇺🇸 "[Ripple was] the first leading U.S. company to be sued by the SEC," @bgarlinghouse says before the Senate."Fortunately, after four years of a hard fought legal battle, we prevailed." https://t.co/xGocFmZWNp ...

Group 1 - Class Action Attorney Juan Monteverde's firm, Monteverde & Associates PC, is investigating Core Scientific, Inc. related to its sale to CoreWeave, Inc. [1] - Upon completion of the proposed transaction, each outstanding share of Core Scientific common stock will be converted into the right to receive 0.1235 shares of CoreWeave Class A common stock [1] - Core Scientific shareholders will own less than 10% of the combined company after the transaction [1] Group 2 - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1] - The firm is headquartered in the Empire State Building, New York City, and has a successful track record in trial and appellate courts, including the U.S. Supreme Court [2]

Core Insights - Class Action Attorney Juan Monteverde's firm, Monteverde & Associates PC, is investigating PB Bankshares Inc. in relation to its proposed sale to Norwood Financial Corp. [1] - The transaction offers PB Bankshares' shareholders the choice of receiving either 0.7850 shares of Norwood common stock or $19.75 in cash for each common share they own, with a proration clause ensuring that 80% of the total consideration is paid in Norwood stock [1] Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has a successful track record in recovering millions for shareholders [1] - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2] Transaction Details - The proposed sale of PB Bankshares to Norwood Financial Corp. includes an option for shareholders to elect their preferred form of compensation, either stock or cash [1] - The proration mechanism is designed to ensure that a significant majority (80%) of the transaction consideration is distributed in the form of Norwood common stock [1]

NOW: 🇺🇸 "[Ripple was] the first leading U.S. company to be sued by the SEC," @bgarlinghouse says before the Senate."Fortunately, after four years of a hard fought legal battle, we prevailed." https://t.co/xGocFmZWNp ...

Core Viewpoint - A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and efficacy of its gene therapy treatment, ELEVIDYS, during the specified Class Period from June 22, 2023, to June 24, 2025 [1][2]. Group 1: Allegations Against Sarepta - The lawsuit claims that Sarepta made false or misleading statements about the safety risks associated with its gene therapy treatment, ELEVIDYS [2]. - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, which could lead to regulatory scrutiny and halt recruitment and dosing in ongoing trials [2]. - The severity of adverse events from ELEVIDYS treatment is said to have been downplayed, resulting in materially misleading statements from the company [2]. Group 2: Lead Plaintiff Process - Investors in Sarepta have until August 25, 2025, to apply to be appointed as lead plaintiffs, representing the interests of the class in the litigation [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial stake in the case [3]. - Participation as a lead plaintiff does not affect the ability of other investors to share in any potential recovery from the lawsuit [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is the law firm handling the class action and has a reputation for prosecuting class actions and recovering significant amounts for victims of corporate misconduct [4]. - The firm encourages affected investors to reach out for more information regarding the lawsuit [4].

Core Points - A shareholder class action lawsuit has been filed against Red Cat Holdings, Inc. alleging that the company made materially false and misleading statements regarding its production capacity and the value of the SRR Contract [1] - The lawsuit claims that the defendants overstated the production capacity of the Salt Lake City Facility and the overall value of the SRR Contract, leading to misleading public statements [1] Legal Information - Shareholders who purchased Red Cat shares between March 18, 2022, and January 15, 2025, and suffered significant losses are encouraged to discuss their legal rights with the law firm Holzer & Holzer [2] - The deadline to request to be appointed as lead plaintiff in the case is July 22, 2025 [3]